| abstract |
The present invention relates to a product consisting of a conglomerate of collagen, in the form of the partly hydrolyzed industrial derivative thereof called gelatine, and an amorphous micronized drug, characterized by a high bioavailability of the micronized active ingredient and a safety of use of the same deriving from the protective action of collagen against the harmful effects of contact with the active ingredient. |